Background: Pyridines have been reported to possess various pharmacological activities.
Introduction
The pyridine core is a key constituent in a scope of bioactive compounds which occur artificially and naturally. It has been appeared to have a wide scope of biological applications [1] [2] [3] . Among these, substituted cyanopyridines were found to have antihypertensive [4] , antipyretic, anti-inflammatory and analgesic properties [5] ; cardiotonic [6] , antimicrobial [7] , and anticancer activities [8, 9] . Among the successful examples as drug candidates possessing the pyridine core are streptonigrone, lavendamycin and streptonigrin, which are depicted in the literature as anticancer agents. Some pyridine derivatives were contemplated for their topoisomerase inhibitory action and cytotoxicity against a few human malignant growth cell lines, thus marking them as novel anticancer agents [10] . Accordingly, it has been accounted those different pyridine derivatives, as bioisosteres of α-terthiophene (protein kinase C inhibitor) [11] , have significant topoisomerase I and II inhibitory activity and cytotoxicity against many human cancer cell lines [12] [13] [14] [15] .
Early reports on the ability of α-terpyridine to form a metal complex [16] and to bind with DNA/RNA [17] have been the reason for the investigation of pyridine derivatives as antitumor agents. In light of the above discoveries and in continuation of our endeavors to synthesize new antitumor compounds [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , the aim of this report is to synthesize a new series of 3-pyridinecarbonitriles, which are anticipated to be active as antitumor agents.
Results and discussion
The synthetic strategies adopted for the synthesis of the intermediates and target compounds are depicted in Schemes 1, 2 and 3. In Schemes 1 and 2, sodium 3-oxo-3-(2-oxo-2H-chromen-3-yl)prop-1-en-1-olate (2) and sodium 3-oxo-3-(3-oxo-3H-benzo[f ]chromen-2-yl)prop-1-en-1-olate (7) were prepared from a reaction of the respective 2-acetyl-3H-benzo[f ]chromen-3-one (1) or 2-acetyl-3H-benzo[f ]chromen-3-one (6) with ethyl formate in dry ether containing sodium methoxide, according to reported methods [28] . The structures of 2 and 7 were confirmed by chemical transformations.
The treatment of sodium salt 2 or 7 with the appropriate 2-cyano-N'-(1-aryl(heteryl) ethylidene)acetohydrazides 3a-d [29] [30] [31] in acetic acid containing piperidine acetate afforded products 5a-d and 9a-d, respectively, in good yields (Schemes 1 and 2).
The structures of the reaction products 5a-d and 9a-d were established and confirmed by their elemental analysis and spectral data (MS, IR, 1 HNMR, 13 CNMR). Thus, the structure of 5a is supported by its mass spectrum, which showed a molecular ion corresponding to the formula C 23 
.
To account for the formation of the products 5a-d and 9a-d, it is suggested that the studied reactions started with a nucleophilic attack by the methylene group of compound 3 at the formyl group of compound 2 or 7, which formed in situ due to the reaction of the formyl salts with water. This resulted in the formation of the non-isolable intermediate 4 or 8, followed by cyclization through the elimination of the water molecule, leading to the formation of the final pyridine derivatives 5 or 9 (Schemes 1 and 2).
Similarly, the 2-cyano-N-(1-substituted ethylidene) acetohydrazides 3a-d reacted with the appropriate sodium (2-oxocyclopentylidene)methanolate (11a) [32] or sodium 2-oxocyclohexylidene)methanolate (11b) [32] in acetic acid containing piperidine acetate to give 2-oxo-1-((1-aryl(heteryl)ethylidene)amino)-1H-cycloalkana[b]pyridine-3-carbonitrile derivatives 13a-h, respectively (Scheme 3). The structure of 13a-d has been assigned as a reaction product on the basis of analytical and spectral data. The IR spectrum displayed absorption bands at 2227 cm As depicted in Scheme 3, the formation of 10 seems to start with an initial attack by a carbanion of the active methylene compound 3 to the formyl group of the salt 11, which formed in situ due to the reaction of the formyl salts 11 with water, forming. Subsequent enolization followed by elimination of water led to product 13.
Antitumor activity
The antitumor activity of compounds 5a-d, 9a-d and 13a-d was determined against a liver carcinoma cell line, HEPG2. Doxorubicin was utilized as a reference drug and showed IC50 = 0.72 μM against this liver carcinoma cell line. Collected data were used to plot a dose-response curve, of which the concentration (μM) of the tested compounds required to kill of 50% of the cell population (IC 50 ). Antitumor activity was expressed as the mean IC 50 of three different experiments.
The outcomes showed that the vast majority of the tested compounds demonstrated extraordinary variable activity contrasted with the reference drug, as shown in Table 1 and Fig. 1 . The descending order of activity of the new compounds was as follows: 5c > 5d > 5a > 13c > 5b > 9a > 9b > 9d > 13d > 13a > 13b.
Examination of the SAR leads to the following conclusions.
The pyridine derivatives 5c and 5d (IC 50 = 1.46, 7.08 µM, respectively) demonstrated potent antitumor activity against HEPG2, while pyridines 5a, 9c, 13c, 5b, 9a, showed moderate activity (IC 50 = 22.3-42.8 µM). The remaining pyridines showed poor antitumor activity against this liver carcinoma cell line (IC 50 > 65 µM).
The pyridine derivatives having coumarine ring 5a-d exhibited more anticancer activity than pyridines having naphthocoumarine ring 9a-d while the latter pyridines 9a-d exhibited more activity than cyclopenta[b]pyridines 13a-d.
Experimental section
Melting points were recorded in open capillaries using an electrothermal Gallenkamp apparatus and are uncorrected. Elemental analyses were carried out by the microanalytical center at Cairo University. The The mass spectra were recorded on GCMSQ1000-EX Shimadzu spectrometers. The IR spectra were measured on a Pye-Unicam SP300 instrument.
Synthesis of the sodium salt of 3-(3-hydroxyprop-2-enoyl)-2H-chromen-2-one (4) and the sodium salt of 2-(-3-hydroxyprop-2-enoyl)-3H-benzo[f]chromen-3-one (7)
Sodium methoxide (0.054 g, 10 mmol) and ether (20 mL) were poured through a separating funnel to a three-necked flask (250 mL), then the appropriate
chromen-3-one (6) (10 mmol of each) and ethyl formate (0.74 g, 10 mmol) were added and stirred. The formed solid products 4 and 7 were collected via filtration and used directly in the following reactions.
Synthesis of 2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 5a-d and 9a-d
An aqueous solution of 4 or 7 (10 mmol of each), the appropriate cyanoacetic acid hydrazones 3a-d (10 mmol) and piperidine acetate (1 mL) was refluxed for 10 min, then acetic acid (1.5 mL) was added to the hot solution. -6-(2-oxo-2H-chromen-3-yl)-1-((1-(3  -oxo-3H-benzo[f]chromen-2-yl) -1-((1-(2-oxo-2H-chromen-3-yl 
2-Oxo

2-Oxo-6-(3-oxo-3H-benzo[f] chromen-2-yl)-1-((1-phenylethylidene) amino)-1,2-dihydropyridine-3-carbonitrile (9a)
Yield
2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-((1-(p-tolyl) ethylidene)amino)-1,2-dihydropyridine-3-carbonitrile (9b)
2-Oxo
2-Oxo-6-(3-oxo-3H-benzo[f]chromen-2-yl)-1-(( 1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene) amino)-1,2-dihydropyridine-3-carbonitrile (9d)
Synthesis of sodium salt of cycloalkanones 11a, b
In a three-necked flask (250 mL), sodium methoxide (0.054 g, 10 mmol) and ether (20 mL) were poured through a separating funnel, the appropriate cyclopentanone (10a) or cyclohexanone (10b) (10 mmol of each) with ethyl formate (0.74 g, 10 mmol) were added, and then stirred. The formed solid products 11a and 11b were collected and used directly in the following reactions.
Synthesis of 2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 13a-h
A solution of 11a or 11b (10 mmol of each), the appropriate cyanoacid hydrazones 3a-d (10 mmol) and piperidine acetate (1 mL) in water (3 mL) was refluxed for 10 min. Acetic acid (1.5 mL) was added to the hot solution. The solid product was filtered off and recrystallized from the proper solvent to give products 13a-h. The physical constants and spectral data of the obtained products 13a-h are listed below: -1-((1-phenylethylidene) -1-((1-(p-tolyl) -1-((1-(2-oxo-2H-chromen-3-yl) -1-((1-phenylethylidene) -1-((1-(p-tolyl) -1-((1-(2-oxo-2H-chromen-3-yl) 
2-Oxo
Evaluation of the antitumor activity using Viability assay
The cytotoxic evaluation of the synthesized compounds was carried out at the Regional Center for Mycology and Biotechnology at Al-Azhar University, Cairo, Egypt, according to a reported method [33] .
Materials and methods
Chemicals
All chemicals used in this study are of high analytical grade. They were obtained from (either Sigma-Alderich or Biorad).
Human tumor cell lines
The tumour cell lines were obtained frozen in liquid nitrogen (− 180 °C) from the American Type Culture Collection (ATCC ® HB-8065 ™ ) and was maintained at the National Cancer Institute, Cairo, Egypt, by serial sub-culturing.
Measurement of potential cytotoxic activity
The cytotoxic activity was measured in vitro on human cancer cell line (HEPG2) using Sulforhodamine-B stain (SRB) assay.
